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Aims: Serious concern has arisen about the cardiovascular safety of selective cyclo-oxygenase-2 
(COX-2) inhibitors. However, recent studies have shown that the cardiovascular risks of regular 
use of traditional analgesics also deserve attention. We investigated the use of traditional anal-
gesics for their prediction of major coronary events during 16 years of follow-up.
Methods: A population sample of 8000 Finns aged 30 years and over was invited to a com-
prehensive health examination in 1978–1980; 7217 (90%) complied, and 4824 of these had no 
diagnosed cardiovascular disease. The participants ﬁ  lled in a questionnaire eliciting informa-
tion on the use of analgesics. Record linkage to the National Hospital Discharge Register and 
the mortality register of the Central Statistical Ofﬁ  ce of Finland identiﬁ  ed 266 major coronary 
events (myocardial infarctions or coronary deaths) by the end of 1994.
Results: The risk of a major coronary event was signiﬁ  cantly elevated among those reporting 
regular use of analgesics at baseline. Compared with nonusers and adjusted for known risk factors 
for coronary heart disease, the relative risk of an event during the whole follow-up period was 1.51 
(95% conﬁ  dence interval [CI] 1.08–2.10) among regular users of analgesics. The risk was as high as 
5.27 (95% CI 2.13–13.11) during the ﬁ  rst two years of the follow-up. Thereafter it leveled off.
Conclusion: Based on sales statistics almost all analgesics used in Finland at the end of the 1970’s 
were nonsteroidal antiinﬂ  ammatory drugs (NSAIDs). Therefore, the increased risk of major 
coronary events among regular users of analgesics is likely to be due to traditional NSAIDs.
Keywords: acute myocardial infarction, coronary heart disease, cohort study, analgesics, 
pharmacology, risk factors
Background
New selective nonsteroidal antiinﬂ  ammatory drugs (NSAIDs) may be prothrombotic 
and increase the risk of myocardial infarction. Such concerns have arisen after the 
unexpected ﬁ  ndings in a study of gastrointestinal toxicity, indicating higher rates of 
myocardial infarction in patients receiving a selective cyclo-oxygenase (COX-2) inhibi-
tor (rofecoxib) as compared with those receiving a traditional nonselective NSAID 
(naproxen).1,2 Other recent studies3–5 also indicate that the use of COX-2 inhibitors 
has increased the risk of serious coronary heart disease.
However, traditional NSAIDs also have complex effects that could either prevent or 
promote coronary heart disease,6 but despite antiinﬂ  ammatory and antiplatelet effects 
similar to those of aspirin these drugs do not protect against myocardial infarction.7 
Recent results from a large population case-control study show an increased risk of 
myocardial infarction with current use of rofecoxib, diclofenac, and ibuprofen, even 
when adjusted for many potential confounders.8 Similar results were found in another 
recent study, in which the relative risk of myocardial infarction was increased in cur-
rent and new users of all classes of nonaspirin NSAIDs.9
Moreover, a recent study suggests that the risk of AMI is increased during several 
weeks after the cessation of NSAID therapy.10 Thus, the cardiovascular safety of all 
NSAIDs should be reconsidered.Therapeutics and Clinical Risk Management 2009:5 10
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Aims
We studied the use of traditional analgesics for their prediction 
of major coronary events in a large, nationally representative 
sample of men and women followed-up for 16 years.
Methods
The study population was a stratiﬁ  ed two-stage cluster sample 
drawn from the population register to represent Finnish adults 
aged 30 years or over.11 In the ﬁ  rst stage, 40 representative 
areas were selected. In the second stage, a systematic sample 
of inhabitants was drawn from each area. The sample con-
sisted of 8,000 persons (3,637 men) of whom 7,217 (90%) 
participated. The study uses material from before current 
legislation on medical research came into force. Thus, partici-
pants were fully informed about the study, they participated 
in it on a voluntary basis, and the use of the information for 
medical research was explained to them.
Details of the design and implementation of the Mini-
Finland Health Survey have been described elsewhere.11,12 
In brief, all participants were interviewed at home and asked 
to ﬁ  ll in a basic questionnaire before attending a screening 
examination. The interview and questionnaire elicited essen-
tial information on health habits and previously diagnosed 
diseases. The screening phase comprised measurements 
and tests to identify subjects with possible cardiovascular, 
respiratory or musculoskeletal diseases. The subjects of the 
present study (n = 4824) were those with no cardiovascular 
disease at the screening phase.
In the basic questionnaire the participants were asked 
about the use of analgesics: Have you in the past three months 
taken any medicine (prescribed or other) for any of the fol-
lowing reasons: headache, backache, muscle or joint ache, 
other ache? If “yes”, do you need this medicine continually 
or nearly so? On the basis of this information the use was 
classiﬁ  ed into none, occasional, or regular.
The basic questionnaire also elicited information on 
free time physical activity categorised into three classes: 
low, moderate, and high activity. Smoking history was 
obtained in a standard interview and categorised as follows: 
never smoked; ex-smoker; current smoker of cigars, pipe 
or of fewer than 20 cigarettes a day; and current smoker of 
20 cigarettes or more a day. Average weekly consumption 
of beer, wine and strong beverages during the preceding 
month were also inquired about. The overall alcohol con-
sumption was then calculated and expressed in grams of 
ethanol per week. The level of education was considered in 
three categories based on the number of years of education. 
Standing height and weight were measured at the screening 
examination, and body mass index (weight/height2, kg/m2) 
was used as a measure of relative weight. Serum cholesterol 
concentrations were determined from serum samples after 
1–3 weeks of storage at −20 °C with an auto analyser modi-
ﬁ  cation of the Liebermann-Burchard reaction. Systolic and 
diastolic blood pressures were measured, using long cuffs 
with 12.5 cm × 40 cm rubber bags according to standard 
protocol. Those using insulin or other antidiabetic drugs, 
and those with clearly elevated fasting blood glucose level 
(over 130 mg/100 ml) and/or abnormal glucose tolerance 
and glucosuria, were considered diabetics.
Morbidity and mortality in the cohort have been con-
tinuously followed since the baseline examination. A major 
coronary event was deﬁ  ned as either myocardial infarction 
or coronary death. Nonfatal cases of myocardial infarc-
tion (ICD-8 code 410) were identiﬁ  ed by linking the study 
population to the nationwide hospital discharge register, 
using the patient’s unique personal identiﬁ  cation number.13 
Cases of fatal coronary heart disease (ICD-8 codes 410–414) 
were identiﬁ  ed from death certiﬁ  cates, which were obtained 
for all the deceased from Statistics Finland. Of multiple 
events at the individual level, only the ﬁ  rst major event was 
registered. During the follow-up period (from the baseline 
examination to the end of 1994) 266 major coronary events 
(coronary deaths or myocardial infarction) occurred among 
men and women (n = 4824) who had not shown cardiovas-
cular disease at baseline.
Statistical Analysis System software (SAS Institute, Cary, 
NC, USA) was used for statistical analysis. Cross-sectional 
associations between known risk factors for coronary heart 
disease and the use of analgesics were analysed with the 
logistic regression model. The Cox’s life-table regression 
model was used to estimate the associations between the use 
of analgesics and major coronary event. Potential confound-
ing and effect-modifying factors were also entered into the 
models. Signiﬁ  cance of interaction was tested by entering 
interaction terms into the models. The 95% conﬁ  dence inter-
vals (CIs) of the relative risk estimates and the likelihood 
ratio statistics (chi-squared values expressed as P values) 
were based on the models.
Results
Of the common factors known to affect the risk of coronary 
heart disease, high age, female sex, high diastolic pressure, 
low serum high density lipoprotein (HDL) cholesterol level, 
low level of education, smoking and low physical activity 
at leisure were signiﬁ  cantly associated with regular use of 
analgesics at baseline (Table 1). Body mass index, systolic Therapeutics and Clinical Risk Management 2009:5 11
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pressure, alcohol intake and diabetes showed no such 
association and were therefore not regarded as confounding 
factors in this study.
After adjustment for the potential confounding factors, 
the risk of major coronary events was signiﬁ  cantly increased 
among the regular users of analgesics, ie, those who had taken 
such a medicine daily or almost daily over three months, 
compared with nonusers (Table 2). The relative risk was 
ﬁ  ve-fold during the ﬁ  rst two years of the follow-up, but 
leveled off thereafter.
Excluding the subjects with chronic inﬂ  ammatory polyar-
thritis did not substantially change the relative risk estimates 
described above. None of the interaction terms between 
the use of analgesics and the potential confounding factors 
Table 1 Adjusted relative risk (RR) and its 95% conﬁ  dence interval (CI) of the use of analgesics occasionally or over three months by 
age, total cholesterol, serum HDL, systolic and diastolic blood pressures, body mass index, sex, level of education, smoking, alcohol intake 
and free time physical activity, and diabetes in Finnish men and women aged 30 years or over without cardiovascular diseases. Logistic 
regression model. Adjusted by age and sex (n = 4824)
Continuous variables* Mean SD RR 95% CI
Age (years) 47.1 12.6 1.45 1.33–1.57
Total cholesterol (mmol/l) 6.8 1.3 1.01 0.93–1.10
Serum HDL cholesterol (mmol/l) 1.7 0.4 0.91 0.83–0.99
Systolic blood pressure (mmHg) 139.2 20.3 0.96 0.87–1.06
Diastolic blood pressure (mmHg) 92.2 9.6 1.09 0.99–1.19
Body mass index (kg/m²) 25.2 3.8 1.04 0.96–1.13
Class variables Analgesics 
users(n)
Subjects 
examined(n)
RR 95% CI
Sex
Male 204 2196 1.00
Female 390 2628 1.64 1.37–1.97
Educational level
8 years 443 3024 1.00
8–12 years 105 1130 0.70 0.56–0.89
12 years 46 670 0.53 0.39–0.74
Smoking status
Never smoked 333 2664 1.00
Ex-smoker 111 941 1.34 1.04–1.72
Pipe, cigars or
20 cigarettes/day 100 760 1.52 1.17–1.96
20 cigarettes/day 50 459 1.50 1.07–2.12
Alcohol intake 
(grams of ethanol per week)
0 307 1944 1.00
1–49 244 2294 0.85 0.70–1.03
50–249 15 209 0.67 0.38–1.17
249 28 377 0.73 0.48–1.13
Leisure time physical activity
Low 273 1516 1.00
Moderate 244 2438 0.55 0.46–0.67
High 76 862 0.54 0.41–0.71
Diabetes
No 582 4723 1.00
Yes 12 101 0.72 0.39–1.33
Note: *For continuous variables the relative risks have been given by an increment of standard deviation (SD).Therapeutics and Clinical Risk Management 2009:5 12
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proved statistically signiﬁ  cant (p = 0.5–0.8) for prediction of 
major coronary events during the 16-year follow-up.
Discussion
In the present study, we found an elevated risk of major 
coronary events among regular users of analgesics. The 
risk remained high only during the ﬁ  rst two years after the 
baseline examination. The absence of a longer effect sug-
gests that the use of analgesics probably does not contribute 
to the development of coronary atherosclerosis but rather 
triggers acute coronary events. The results suggest that 
during the past decades a substantial proportion of major 
coronary events have been attributable to the traditional 
analgesics.
One of the strengths of our study is that it was based on a 
large, nationally representative health examination survey of 
those aged 30 years or over. Moreover, the follow-up period 
in our study extended up to 16 years, clearly exceeding those 
in previous studies on the same topic.8,9,14,15 The Finnish 
National Hospital Discharge Register operating since 1967 
contains information on hospital admissions and discharges 
from every hospital in the country. This information includes, 
along with a personal identiﬁ  cation code, the primary and 
secondary diagnoses according to the International Clas-
siﬁ  cation of Diseases. By means of these data we were able 
to identify those study subjects who had been hospitalised 
for myocardial infarction since the baseline examination. 
Because myocardial infarction is a severe disease, practically 
all patients with this condition are likely to be admitted to 
hospital for acute care. The diagnosis of myocardial infarc-
tion had been correctly registered at the three-digit level in 
the National Hospital Discharge Register in 84.7% of the 
hospitalised patients, when checked against the original hos-
pital documents.13 Thus, the discharge register information 
is sufﬁ  ciently valid for prediction of myocardial infarction 
at the national level.
A major limitation of our study is the absence of speciﬁ  c 
information on the names and amounts of the analgesics used 
by the subjects at the time of the baseline study. However, 
the role of analgesics can be estimated on the basis of sales 
statistics of these drugs. At the time of the baseline study the 
sales statistics of simple NSAID preparations in Finland was 
topped by acetylsalicylic acid,16 followed by indomethacin, 
ibuprofen, naproxen, and ketoprofen (Figure 1). The use of 
paracetamol was very low in Finland at the time of the baseline 
study,16 (Figure 1.) and antimigraine preparations were also of 
little importance since they were not used on a regular basis.16 
Most importantly, our results cannot be confounded by selec-
tive COX-2 inhibitors, because they were ﬁ  rst introduced after 
the end of the follow-up period. Thus, most of the preparations 
used regularly for pain relief in this study cohort were likely to 
be traditional NSAIDs. It appears, therefore, that the increased 
risk of major coronary events in the present study is associated 
with regular use of traditional NSAIDs. However, analgesics 
use was only assessed at baseline which may not necessarily 
indicate long-term use throughout the follow-up. Furthermore, 
Table 2 The relative risk (RR) and its 95% conﬁ  dence interval (CI) of major coronary event at follow-up in Finnish men and women 
aged 30 years or over, who have used analgesics, but with no cardiovascular disease at baseline. Cox model
Use of analgesics Analgesics 
users
Subjects 
examined
Adjusted by age and sex Complete model*
n n RR 95% CI RR 95% CI
The whole follow-up
None 128 2440 1.00 1.00
Occasionally 88 1790 1.27 0.96–1.67 1.20 0.91–1.58
Regular over 3 months 51 594 1.69 1.22–2.35 1.51 1.08–2.10
Follow-up of 2 years
None 9 2440 1.00 1.00
Occasionally 4 1790 0.91 0.28–3.00 1.04 0.31–3.48
Regular over 3 months 12 594 5.22 2.18–12.46 5.27 2.13–13.11
Follow-up from 2 to 16 years
None 119 2408 1.00 1.00
Occasionally 84 1777 1.28 0.97–1.71 1.20 0.90–1.59
Regular over 3 months 39 575 1.40 0.97–2.02 1.23 0.85–1.78
Note: *Adjusted by age, sex, diastolic blood pressure, serum HDL, level of education, smoking, and free time physical activity.Therapeutics and Clinical Risk Management 2009:5 13
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the lack of speciﬁ  c information on the analgesics and their 
dosing schemes does not allow any conclusion regarding 
possible causality between speciﬁ  c drugs and cardiovascular 
risk. Moreover, it has been suggested that concurrent use of 
acetosalisylic acid should be taken into account because this 
medicine could mitigate an increased risk of coronary events 
among some patients using other NSAIDs.17 However, our 
results are unlikely to be confounded by such joint medication 
because low-dose acetosalisylic acid was not used in Finland 
at the time of the baseline examination.
An association between NSAIDs and cardiovascular risk 
was ﬁ  rst reported about COX-2 selective preparations.1,3–5 
Recent studies, however, also linked an increased risk of 
myocardial infarction with the use of traditional NSAIDs 
which inhibit both COX-1 and COX-2 receptors.8,9 Further, 
a recent large follow-up study showed an increased risk of 
myocardial infarction with the use of indomethacin (+71%), 
sulindac (+41%), and meloxicam (+37%).14 Among the 
COX-2 inhibitors, rofecoxib showed the highest risk (+32%), 
followed by celecoxib (+9%).14 The authors suggested that 
the increased risk for myocardial infarction results from a 
class effect of NSAIDs.14 Similarly, the Finnish popula-
tion-based matched case-control study showed a modestly 
increased risk of ﬁ  rst myocardial infarction associated with 
the current use of all NSAIDs.15
Moreover, in a prospective cohort of 70,971 women it 
was found that the risk for major cardiovascular events was 
associated with the use of NSAIDs or acetaminophen at 
high frequency or dose, particularly among current smok-
ers.18 There was no increased risk with the less than daily 
use of NSAIDs or acetaminophen.18 It is well known that 
low-dose acetylsalicylic acid (50–250 mg/day) is highly 
cardioprotective, when it because of irreversible inactivation 
of platelet COX-1 activity for up to 10 days.19 However, 
there is evidence that high-dose acetylsalicylic acid (over 
325 mg/day) can modestly increase the risk of myocardial 
infarction similarly to other conventional NSAIDs.14,20 
The high-dose acetylsalicylic acid therapy may even then 
provide cardioprotective beneﬁ  ts in long term use.21 Since 
acetylsalicylic acid was the most sold analgesic at the base-
line of the present study, it is obvious that it was used as a 
high-dose analgesic, not as a low-dose cardioprotector. The 
previous studies also demonstrated that the regular use of any 
NSAIDs with high dose is particularly harmful for patients 
with known risk factors for coronary heart disease, such as 
tobacco smoking.
According to a recent meta-analysis, there was an increase 
of 42% (relative risk 1,42; 95% CI 1.13–1.78) in the vas-
cular events, mainly myocardial infarction, among users of 
selective COX-2 inhibitors,22 whereas nonselective NSAIDs 
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Figure 1 Sales statistics of simple analgesic preparations in Finland during the baseline study from 1978 to 1980 (excluding sales to hospitals).16*
Notes: *The deﬁ  ned daily dose (DDD) is based on the average daily dose used for the main indication of the drug. Drug utilization in DDDs per 1000 inhabitants per day 
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as a class showed an increase of 19% (relative risk 1,19; 
CI 1.08–1.31).23 Although the overall relative risk appears 
to be small, the absolute risk may be considerable due to the 
large number of patients prescribed NSAIDs.24
The mechanism behind these associations between 
NSAID use and cardiovascular risks is partially unknown. 
Nevertheless, the isozymes, cyclooxygenase-1 (COX-1) 
and cyclooxygenase-2 (COX-2), are known to catalyze the 
conversion of arachidonic acid to eicosanoids that play an 
important role in the maintenance of cardiovascular hemo-
stasis. Thromboxane A2, primarily synthesized by platelet 
COX-1, causes irreversible platelet aggregation, vasoconstric-
tion and smooth muscle proliferation. In contrast, vascular 
prostaglandin I2, which appears to be synthesized by COX-2, 
counteracts most of the effects exerted by thromboxane A2. 
Inhibition of the COX isozymes by regular use of traditional 
NSAIDs or new COX-2 selective inhibitors may therefore 
disturb the balance between these two routes through which 
vasoactive eicosanoids are formed. This results in platelet 
aggregation, vasoconstriction, myocardial infarction and cor-
onary death.25 It is also well documented that, most NSAIDs 
raise blood pressure (approximately 3–5 mmHg) by inhibiting 
prostacyclin in the kidney with resultant sodium and water 
retention, and hypertension.26–28 Even such a modest rise in 
systolic blood pressure can increase the frequency of conges-
tive cardiac failure by 10%–20% and angina by 12%.29
Conclusions
In conclusion, our results support recent observations sug-
gesting that the risk of major coronary events associated 
with regular use of NSAIDs is not conﬁ  ned to the use of 
selective COX-2 inhibitors, but also involves traditional 
NSAIDs. Patient selection rather than drug selectivity may 
thus be more important, and the lowest possible dose should 
be used for the shortest possible duration. In the present 
study, the use of analgesics predicted major coronary events 
predominantly during the ﬁ  rst two years after the baseline 
examination indicating that the risk of these events is likely 
to be reversible. Despite the limitations of previous studies 
and the present one, doctors should be aware of this risk, 
especially when treating patients with known risk factors 
for coronary heart disease. Further prospective studies on 
speciﬁ  c drugs are needed to clarify the effects of these widely 
prescribed therapies.
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